Genetic predisposition to early breast cancer in Kazakh women

“Our study may reveal previously uncharacterized population-specific variants that may increase the risk of BC in the Kazakh population.” Credit: 2023 Zhunussova et al. “Our study may reveal previously uncharacterized population-specific variants that may increase the risk of BC in the Kazakh population.” BUFFALO, NY- November 22, 2023 – A new research paper was published […]

Nov 23, 2023 - 18:00

Genetic predisposition to early breast cancer in Kazakh women

“Our study may reveal previously uncharacterized population-specific variants that may increase the risk of BC in the Kazakh population.”

Credit: 2023 Zhunussova et al.

“Our study may reveal previously uncharacterized population-specific variants that may increase the risk of BC in the Kazakh population.”

BUFFALO, NY- November 22, 2023 – A new research paper was published in Oncotarget’s Volume 14 on October 4, 2023, entitled, “Determination of genetic predisposition to early breast cancer in women of Kazakh ethnicity.”

Breast cancer (BC) is the most common type of cancer among women in Kazakhstan. To date, little data are available on the spectrum of genetic variation in Kazakh women with BC.

In this new study, researchers Gulnur Zhunussova, Nazgul Omarbayeva, Dilyara Kaidarova, Saltanat Abdikerim, Natalya Mit, Ilya Kisselev, Kanagat Yergali, Aigul Zhunussova, Tatyana Goncharova, Aliya Abdrakhmanova, and Leyla Djansugurova from the Institute of Genetics and Physiology, Kazakh Institute of Oncology and Radiology, Al-Farabi Kazakh National University, and Asfendiyarov Kazakh National Medical University aimed to identify population-specific genetic markers associated with the risk of developing early-onset BC and test their association with clinical and prognostic factors.

“To our knowledge, this is the first study using NGS [next-generation sequencing] technology to study the genetic predisposition to early-onset BC women from Kazakhstan and assess their impact on the patients’ clinical outcomes.”

The study included 224 Kazakh women diagnosed with BC (≤40 age). Entire coding regions (>1700 exons) and the flanking noncoding regions of 94 cancer-associated genes were sequenced from blood DNA using MiSeq platform. The researchers identified 38 unique pathogenic variants (PVs) in 13 different cancer-predisposing genes among 57 patients (25.4%), of which 6 variants were novel. In total, 12 of the 38 distinct PVs were detected recurrently, including BRCA1 c.5266dup, c.5278-2del, and c.2T>C, and BRCA2 c.9409dup and c.9253del that may be founder in this population. BRCA1 carriers were significantly more likely to develop triple-negative BC (OR = 6.61, 95% CI 2.44–17.91, p = 0.0002) and have family history of BC (OR = 3.17, 95% CI 1.14–8.76, p = 0.03) compared to non-carriers.

“This study allowed the identification of PVs specific to early-onset BC, which may be used as a foundation to develop regional expertise and diagnostic tools for early detection of BC in young Kazakh women.”

Read the full paper: DOI: https://doi.org/10.18632/oncotarget.28518

Correspondence to: Gulnur Zhunussova, Nazgul Omarbayeva

Emails: gulnur_j@outlook.com, nomarbayeva1@gmail.com

Keywords: early-onset breast cancer, triple negative breast cancer, next-generation sequencing, pathogenic variant, Kazakh population

About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media: